RESPONSIVENESS OF CLOPIDOGREL AFTER CORONARY ARTERY STENTING

被引:0
|
作者
Habib, Ayesha [1 ]
Tariq, Sayyab [2 ]
Amjad, Sidra [2 ]
机构
[1] King Edward Med Univ, Lahore, Pakistan
[2] Holy Family Hosp, New Delhi, India
来源
关键词
Clopidogrel; resistance; percutaneous coronary intervention (PCI); P2Y12 platelet aggregation;
D O I
10.5281/zenodo.1405115
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Antiplatelet therapy prescribed in combination has been in practice all over the globe. The non-respondents are then put on interventional procedures like coronary artery stenting. Aspirin and clopidogrel 300mg each are used as anti-ischemic in patients with acute coronary syndrome. Objective: The aim of study is to find resistance of clopidogrel after coronary artery intervention. Methods: Study was conducted at department of cardiology, Mayo Hospital, Lahore, Pakistan. Study duration was one year from June 2016 to July 2017. 4 to 6 hours before PCI all patients were given 600mg clopidogrel and later were advised clopidogrel and aspirin 75mg each. A blocking analysis test was performed on P2Y12 after collecting venous blood sample. Test results were categorized into resistant, hypo-reactive and receiver based on closing time, <106 seconds, between 106 to 224seconds and >225 seconds, respectively. Demographic profile and risk factors for ACS were inquired from all participants. Results: Total study population was 50 patients who were to undergo PCI including 38 males and 12 females. Fifteen were resistant (30%), 5 were hypo-reactive (10%), 30 were receivers (60%). All patients remained free from any coronary event till 4 weeks after PCI. Conclusion: More than one third of post PCI population was resistant or hypo-reactive to clopidogrel.
引用
收藏
页码:8057 / 8059
页数:3
相关论文
共 50 条
  • [1] Variable extent of clopidogrel responsiveness in patients after coronary stenting
    Grossmann, R
    Sokolova, O
    Schnurr, A
    Bonz, A
    Porsche, C
    Obergfell, A
    Lengenfelder, B
    Walter, U
    Eigenthaler, M
    THROMBOSIS AND HAEMOSTASIS, 2004, 92 (06) : 1201 - 1206
  • [2] Clopidogrel for Long-Term Secondary Prevention After Coronary Artery Stenting
    Bellemain-Appaix, Anne
    Montalescot, Gilles
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (01) : 32 - 34
  • [3] Comparison of Efficacy and Safety of Treatment With Drugs of Clopidogrel in Patients After Coronary Artery Stenting
    Avdeeva, L. V.
    Shtegman, O. A.
    Mosina, V. A.
    KARDIOLOGIYA, 2011, 51 (07) : 23 - 26
  • [4] CO-EXISTENCE OF HYPO-RESPONSIVENESS TO ASPIRIN AND CLOPIDOGREL IN EMERGENCY ROOM IN PATIENTS WITH CORONARY ARTERY STENTING
    Sharma, R. K.
    Erickson, S. W.
    Sharma, R.
    Reddy, H. K.
    Voelker, D. J.
    Dod, H.
    Singh, V. N.
    Murgasen, E. I.
    Marsh, J. D.
    CARDIOLOGY, 2013, 125 : 427 - 427
  • [5] Coronary artery stenting in patients treated by clopidogrel without aspirin
    Rott, David
    Leibowitz, David
    Amit, Guy
    Zahger, Doron
    Weiss, A. Teddy
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 133 (02) : 279 - 281
  • [6] Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
    Sharma, Rakesh K.
    Reddy, Hanumanth K.
    Singh, Vibhuti N.
    Sharma, Rohit
    Voelker, Donald J.
    Bhatt, Girish
    VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 : 965 - 972
  • [8] Combination therapy with clopidogrel and aspirin after coronary stenting
    Kolansky, DM
    Klugherz, BD
    Curran, SC
    Herrmann, HC
    Magness, K
    Wilensky, RL
    Hirshfeld, JW
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2000, 50 (03) : 276 - 279
  • [9] CLOPIDOGREL THERAPY FOLLOWING CORONARY ARTERY STENTING IN ACUTE CORONARY SYNDROME PATIENTS
    Hissan, Muhammad Saqib
    Ashraf, Sabah
    Saeed, Muhammad Talha
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (06): : 11526 - 11528
  • [10] CLOPIDOGREL TREATMENT AFTER CORONARY STENTING IN ACUTE CORONARY SYNDROME PATIENTS
    Nasir, Hira
    Khawar, Shanaza
    Hasan, Wazir Muhammad
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 5 (12): : 16132 - 16134